These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 28923214

  • 1. Commentary: Somatostatin analogs-How we choose, and why.
    Reidy-Lagunes D, Raj N, Saltz L.
    Semin Oncol; 2017 Apr; 44(2):157-158. PubMed ID: 28923214
    [No Abstract] [Full Text] [Related]

  • 2. Established clinical use of octreotide and lanreotide in oncology.
    Oberg K.
    Chemotherapy; 2001 Apr; 47 Suppl 2():40-53. PubMed ID: 11275701
    [Abstract] [Full Text] [Related]

  • 3. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M, Strosberg J.
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [Abstract] [Full Text] [Related]

  • 4. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
    Gardner-Roehnelt NM.
    Clin J Oncol Nurs; 2012 Feb; 16(1):56-64. PubMed ID: 22297008
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H.
    Int J Mol Sci; 2019 Jun 22; 20(12):. PubMed ID: 31234481
    [Abstract] [Full Text] [Related]

  • 6. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K.
    Ann Oncol; 2001 Jun 22; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [Abstract] [Full Text] [Related]

  • 7. Somatostatin Analogues in Neuroendocrine Tumors.
    Kulke MH.
    J Natl Compr Canc Netw; 2016 Mar 22; 14(3):241-2. PubMed ID: 26957610
    [No Abstract] [Full Text] [Related]

  • 8. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK, Fong MK, Iyer R.
    Curr Oncol Rep; 2016 Jan 22; 18(1):7. PubMed ID: 26743514
    [Abstract] [Full Text] [Related]

  • 9. Novel therapeutic strategies for neuroendocrine tumours--can eminence replace evidence?
    Zedenius J.
    Acta Oncol; 2008 Jan 22; 47(1):3-4. PubMed ID: 17891671
    [No Abstract] [Full Text] [Related]

  • 10. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
    Igaz P.
    Orv Hetil; 2014 Nov 30; 155(48):1908-12. PubMed ID: 25417137
    [Abstract] [Full Text] [Related]

  • 11. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
    Bousquet C, Lasfargues C, Chalabi M, Billah SM, Susini C, Vezzosi D, Caron P, Pyronnet S.
    J Clin Endocrinol Metab; 2012 Mar 30; 97(3):727-37. PubMed ID: 22170729
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil.
    Valentim J, Passos V, Mataveli F, Calabró A.
    Arq Bras Endocrinol Metabol; 2008 Dec 30; 52(9):1452-60. PubMed ID: 19197453
    [Abstract] [Full Text] [Related]

  • 13. The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy.
    Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L.
    Ann Oncol; 2001 Dec 30; 12 Suppl 2():S105-9. PubMed ID: 11762334
    [Abstract] [Full Text] [Related]

  • 14. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
    Janson ET, Oberg K.
    Cancer Chemother Biol Response Modif; 2003 Dec 30; 21():535-46. PubMed ID: 15338762
    [No Abstract] [Full Text] [Related]

  • 15. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
    Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A, Benavent M, Alonso V, Riesco MDC, Alonso-Gordoa T, Custodio A, Sanchez Canovas M, Hernando J, López C, La Casta A, Fernandez Montes A, Marazuela M, Crespo G, Diaz JA, Feliciangeli E, Gallego J, Llanos M, Segura A, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle J, Garcia-Carbonero R.
    Neuroendocrinology; 2022 Dec 30; 112(1):88-100. PubMed ID: 33508849
    [Abstract] [Full Text] [Related]

  • 16. Antitumor effects of somatostatin analogs in neuroendocrine tumors.
    Sidéris L, Dubé P, Rinke A.
    Oncologist; 2012 Dec 30; 17(6):747-55. PubMed ID: 22628056
    [Abstract] [Full Text] [Related]

  • 17. New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
    Weber M.
    Clin Adv Hematol Oncol; 2014 Dec 30; 12(12 Suppl 19):12-7. PubMed ID: 25768104
    [No Abstract] [Full Text] [Related]

  • 18. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
    Strosberg J, Kvols L.
    World J Gastroenterol; 2010 Jun 28; 16(24):2963-70. PubMed ID: 20572298
    [Abstract] [Full Text] [Related]

  • 19. Somatostatin analogs in acromegaly.
    Freda PU.
    J Clin Endocrinol Metab; 2002 Jul 28; 87(7):3013-8. PubMed ID: 12107192
    [No Abstract] [Full Text] [Related]

  • 20. [Somatostatin analogs].
    Krysiak R, Okopień B, Herman ZS.
    Pol Arch Med Wewn; 2006 Oct 28; 116(4):988-97. PubMed ID: 18416302
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.